Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis

Table 2

B lymphoma patient characteristics.

Sera analysis
	Responders; (𝑛=8)	Nonresponders; (𝑛=5)
Median age (years)	56 (52–79)	59
Gender (M/F)	7/1	2/3
Histology
Diffuse large B cells	7	1
Indolent	1	4
Stage
I/II	3	2
III/IV	5	3
Treatment
Rituximab monotherapy	5	1
Rituximab chemotherapy	3	4